γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C
A cross-sectional study
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Niemann-Pick disease type C (NPC) is an inherited disorder characterized by intracellular accumulation of lipids such as cholesterol and glycosphingolipids in endosomes and lysosomes. This accumulation induces progressive degeneration of the nervous system. NPC shows some intriguing similarities with Alzheimer disease (AD), including neurofibrillary tangles, but patients with NPC generally lack amyloid-β (Aβ) plaques. Lipids affect γ-secretase-dependent amyloid precursor protein (APP) metabolism that generates Aβ in vitro, but this has been difficult to prove in vivo. Our aim was to assess the effect of altered lipid constituents in neuronal membranes on amyloidogenic APP processing in humans.
Methods: We examined Aβ in CSF from patients with NPC (n = 38) and controls (n = 14). CSF was analyzed for Aβ38, Aβ40, Aβ42, α-cleaved soluble APP, β-cleaved soluble APP, total-tau, and phospho-tau.
Results: Aβ release was markedly increased in NPC, with a shift toward the Aβ42 isoform. Levels of α- and β-cleaved soluble APP were similar in patients and controls. Patients with NPC had increased total-tau. Patients on treatment with miglustat (n = 18), a glucosylceramide synthase blocker, had lower Aβ42 and total-tau than untreated patients.
Conclusion: Increased CSF levels of Aβ38, Aβ40, and Aβ42 and unaltered levels of β-cleaved soluble APP are consistent with increased γ-secretase-dependent Aβ release in the brains of patients with NPC. These results provide the first in vivo evidence that neuronal lipid accumulation facilitates γ-secretase-dependent Aβ production in humans and may be of relevance to AD pathogenesis.
Footnotes
Study funding: Supported by the Swedish Research Council (projects 14002, 2006-6227, 2006-2740, and 2006-3505), the Alzheimer's Association (NIRG-08-90356), cNEUPRO, the Royal Swedish Academy of Sciences, Sahlgrenska University Hospital, the Söderberg Foundation, the Gothenburg Medical Society, the Swedish Medical Society, Swedish Brain Power, Stiftelsen Gamla Tjänarinnor, the Lundbeck Foundation, Gun och Bertil Stohnes stiftelse, Åhlén-stiftelsen, The Swedish Brain Fund, Alzheimer Foundation, Sweden, The Dementia Association, Sweden, a Bench to Bedside grant from the NIH Office of Rare Diseases, and the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Editorial, page 316
Supplemental data at www.neurology.org
References e1–e18 are available on the Neurology® Web site at www.neurology.org.
-
- AD
- Alzheimer disease
- APP
- amyloid precursor protein
- CV
- coefficient of variation
- NICHD
- National Institute of Child Health and Development
- NPC
- Niemann-Pick disease type C
- P-tau
- phosphorylated tau
- Received June 9, 2010.
- Accepted September 9, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Amyloidogenic processing of β-amyloid precursor protein in intracellular compartmentsKulandaivelu S. Vetrivel, Gopal Thinakaran et al.Neurology, December 16, 2005 -
Article
Clinical, ocular motor, and imaging profile of Niemann-Pick type C heterozygosityTatiana Bremova-Ertl, Clara Sztatecsny, Matthias Brendel et al.Neurology, March 31, 2020 -
Articles
Biochemical markers in persons with preclinical familial Alzheimer diseaseJ. M. Ringman, S. G. Younkin, D. Pratico et al.Neurology, May 28, 2008 -
Articles
Development of a Suspicion Index to aid diagnosis of Niemann-Pick disease type CF.A. Wijburg, F. Sedel, M. Pineda et al.Neurology, April 18, 2012